Electrocardiographic (ECG) abnormalities are common in older adults. However, performing routine ECG among asymptomatic adults is not supported by current evidence. Considering the higher prevalence of both cardiovascular disease (CVD) and ECG abnormalities in older adults, risk prediction incorporating ECG might be more useful in this group.
To date, few studies have examined the improvement of CVD risk prediction using ECG abnormalities in a population of older adults, and none could adequately adjust the analyses for presence of previous CVD and traditional cardiovascular risk factors (CVRFs). In a study to determine whether minor and major ECG abnormalities at the start of the research, as well as developing new ECG abnormalities and persistent ECG abnormalities during follow-up, were linked to new events of CHD, independent of traditional cardiovascular risk factors, Reto Auer, M.D., of the University of Lausanne in Switzerland, and the University of California in San Francisco, and his team recruited 2,192 white and black adults, aged between 70 to 79 years, who had no known cardiovascular disease.

Over 8 years, from 1997/98 to 2006/07, the authors noted adjudicated CHD events and categorized ECG abnormalities that occurred at the start of the study and at 4-years. To predict CHD events, they examined ECG abnormalities that occurred in addition to the traditional risk factors. The study findings demonstrated that 506 or 23% of the 2,192 participants had major ECG abnormalities, whilst 276 or 13% had minor ones.

Adding Vorapaxar to standard treatment for patients with a medical history of cardiovascular events or disease was found to reduce cardiovascular events, but also increased bleeding significantly, including intracranial hemorrhage. The researchers added that ICH (intracranial hemorrhage) risk was lower for those with no history of stroke.
The trial, called the TRA-2P (Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) TIMI 50 study, focused on the safety and efficacy of Vorapaxar, an experimental anti-thrombotic medication. The experimental drug was being tested for acute coronary syndrome chest pain caused by coronary artery disease.
The human study showed that adding Vorapaxar to thienopyridine, aspirin, or both (standard care) considerably reduced the risk of composite cardiovascular death, stroke, heart attack, or urgent coronary revascularization.

Asperger syndrome (AS) is a pervasive developmental disorder characterized by an inability to understand how to interact socially. Other features include clumsy and uncoordinated motor movements, social impairment with extreme egocentricity, limited interests and/or unusual preoccupations, repetitive routines or rituals, speech and language peculiarities, and non-verbal communication problems. Generally, children with AS have few facial expressions apart from anger or misery. Most have excellent rote memory and musical ability, and become intensely interested in one or two subjects (sometimes to the exclusion of other topics). They may talk at length about a favorite subject or repeat a word or phrase many times. Children with AS tend to be “in their own world” and preoccupied with their own agenda. The onset of AS commonly occurs after the age of 3. Some individuals who exhibit features of autism (a developmental brain disorder characterized by impaired social interaction and communication skills) but who have well-developed language skills may be diagnosed with AS.
There is no specific course of treatment or cure for AS. Treatment, which is symptomatic and rehabilitational, may include both psychosocial and psychopharmacological interventions such as psychotherapy, parent education and training, behavioral modification, social skills training, educational
interventions, and/or medications including psychostimulants, mood stabilizers, beta
blockers, neuroleptics, and tricyclic antidepressants.